Document is current
Any future updates will be listed below
-
Authors
Gupta, Raghav http://orcid.org/0000-0002-5497-3241
Das, Chandan K.
Nair, Sujit S.
Pedraza-Bermeo, Adriana Marcela http://orcid.org/0000-0003-3275-7019
Zahalka, Ali H.
Kyprianou, Natasha
Bhardwaj, Nina http://orcid.org/0000-0003-1865-4187
Tewari, Ashutosh K. http://orcid.org/0000-0002-3146-4524
- License Information
-
More Information
Article History
Accepted: 17 June 2024
First Online: 2 August 2024
Competing interests
: N.K. serves on the advisory board for Onconox Inc. and has received funding from the NCI/NIH for her grant: R01 CA232574-01A1. N.B. is an extramural member of the Parker Institute for Cancer Immunotherapy, Carisma Therapeutics, Curevac, Genotwin, Novartis, Primevax, Rome Therapeutics and Tempest Therapeutics. N.B. receives research funds from Dragonfly Therapeutics, Harbour Biomed Sciences, Regeneron Pharmaceuticals Inc. and the Ludwig Institute for Cancer Research. A.K.T. has served as a site-PI on sponsored clinical trials from Kite Pharma Inc., Lumicell Inc., Dendron Pharmaceuticals, LLC., Oncovir Inc., Blue Earth Diagnostics Ltd., RhoVac ApS., Bayer HealthCare Pharmaceuticals Inc. and Janssen Research and Development, LLC. A.K.T. has also served as an unpaid consultant to Roivant Biosciences and as an adviser to Promaxo. He owns equity in Promaxo. R.G., C.K.D., S.S.N., A.M.P.-B. and A.H.Z. declare no competing interests.
